Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial
- 1 June 2005
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16_suppl) , 4542
- https://doi.org/10.1200/jco.2005.23.16_suppl.4542
Abstract
4542 Background: Most pts with clear cell RCC have loss of Von Hippel Lindau (VHL) protein primarily due to gene mutation, ultimately resulting in overexpression of vascular endothelial growth factor (VEGF), transforming growth factor (TGF-:), epidermal growth factor (EGF), and platelet-derived growth factor (PDGF). In a previous phase II trial, we demonstrated that combined VEGF/EGF receptor inhibition with bevacizumab and erlotinib was an active and well tolerated treatment for pts with metastatic RCC. In this phase I/II trial, we add imatinib, a PDGF receptor antagonist, to the combination of bevacizumab/erlotinib. Methods: Eligibility: metastatic clear cell RCC, 0–2 previous systemic regimens, ECOG PS 0–1, no previous anti-angiogenesis or EGF receptor inhibitor therapy, no active CNS metastases, adequate organ function, no history of thromboembolic disease, informed consent. All pts received bevacizumab 10mg/kg IV q 2 weeks, and erlotinib 150mg po daily. In the phase I portion of the trial, imatinib l...Keywords
This publication has 0 references indexed in Scilit: